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 Clinical signs of UMN involvement are an important component in diagnosis of ALS.
 Novel neuroimaging and electrophysiology may facilitate demonstration of UMN degeneration in ALS.
 Improving early ALS diagnosis can facilitate the development of effective therapies.
a b s t r a c t
Clinical signs of upper motor neuron (UMN) involvement are an important component in supporting the
diagnosis of amyotrophic lateral sclerosis (ALS), but are often not easily appreciated in a limb that is con-
currently affected by muscle wasting and lower motor neuron degeneration, particularly in the early
symptomatic stages of ALS. Whilst recent criteria have been proposed to facilitate improved detection
of lower motor neuron impairment through electrophysiological features that have improved diagnostic
sensitivity, assessment of upper motor neuron involvement remains essentially clinical. As a result, there
is often a significant diagnostic delay that in turn may impact institution of disease-modifying therapy
and access to other optimal patient management. Biomarkers of pathological UMN involvement are also
required to ensure patients with suspected ALS have timely access to appropriate therapeutic trials. The
present review provides an analysis of current and recently developed assessment techniques, including
novel imaging and electrophysiological approaches used to study corticomotoneuronal pathology in ALS.
 2016 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. This is an
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The term amyotrophic lateral sclerosis was first coined by Char-
cot, who postulated the primacy of the upper motor neuron in ALS
pathogenesis (Charcot and Joffroy, 1869) with loss of Betz cells in
the motor cortex being a well-recognised pathological feature
(Kaufmann et al., 2004). The clinical diagnosis of classical amy-
otrophic lateral sclerosis (ALS) is determined by identification of
progressive dysfunction of both cortical (‘upper’) and spinal
(‘lower’) motor neurons across multiple body regions (chiefly limb
and bulbar), much of which was encapsulated by the El Escorial cri-
teria (Brooks, 1994; Brooks et al., 2000b). The variable mix of upper
motor neuron (UMN) and lower motor neuron (LMN) signs con-
tribute to the clinical heterogeneity of ALS (Sabatelli et al., 2011).
The initial clinical presentations constituting 90% of all ALS, may
be classified according to region: (1) limb-onset ALS; (2) bulbar-
onset ALS; or sub-divided into much rarer extremes of LMN or
UMN involvement: (1) progressive muscular atrophy, with pure
LMN involvement, and typically limb-onset; or (2) primary lateral
sclerosis, characterised by predominant UMN involvement, typi-
cally lower limb or bulbar in site of onset, both of which are rare
(Kiernan et al., 2011). While ALS or Lou Gehrig’s disease is the term
used to describe all forms of the disease in the USA, motor neuron
disease (MND) is the preferred term in Australia and the UK, with
ALS reserved for the classical phenotype that presentswith a combi-
nationof upper and lowermotorneuron involvement. In this review,
the termMND/ALSwill beused to encompass all clinical phenotypes
that include the classic ALS, progressive bulbar palsy, progressive
muscular atrophy (PMA), and primary lateral sclerosis (PLS).
In the presence of progressive LMN weakness, features of UMN
involvement are an important component supporting the diagnosis
of MND/ALS (de Carvalho, 2012), but often clinical signs of UMN
dysfunction may not be easily appreciated in a limb that is concur-
rently affected by LMN degeneration particularly in the early
stages of MND/ALS (Swash, 2012; Geevasinga et al., 2014). Clinical
UMN signs are found to be initially absent in 7–10% of MND
patients (Rocha and Maia Júnior, 2012). UMN dysfunction may be
identified by the presence of some or all of hyperreflexia with
pathological reflex spread, spasticity, and clonus, preserved
reflexes in weak wasted limbs and Babinski sign (Brooks et al.,
2000b); as well as in some cases, the paucity or impairment in
motor control and clumsiness may often be early features of
UMN deficit. However, the various components of the UMN syn-
drome reflect different physiological abnormalities in the descend-
ing motor system that is expressed by the intact LMN system, the
latter being invariably affected in MND/ALS (Pierrot-Deseilligny
and Burke, 2005; Swash, 2012). Furthermore, simultaneous alpha
and gamma spinal motor neuron loss in conjunction with spinal
interneuron degeneration has an effect on the expression of UMN
signs (de Carvalho, 2012; Swash, 2012).Objective UMN markers are critical to the diagnosis, as purely
LMN syndromes may be caused not only by MND/ALS (Turner
et al., 2013; Simon et al., 2014), but mimics including progressive
muscular atrophy, various motor neuropathies, Kennedy’s disease
and adult-onset spinal muscular atrophy (SMA). Importantly,
autopsy reports have identified UMN degeneration in 50–75%
patients without apparent clinical signs affecting the corticospinal
tract (Lawyer and Netsky, 1953; Ince et al., 2003; Kaufmann et al.,
2004). Failure to recognise UMN features in patients presenting
with suspected MND/ALS consequently results in diagnostic uncer-
tainty and thereby delay which according to population studies is
more than a year from symptom onset to diagnosis. This will inevi-
tably delay the commencement of potentially disease modifying or
neuroprotective therapy, most effective when started early in the
disease course, in addition to adversely affecting enrolment into
therapeutic trials (Turner et al., 2009; Hardiman et al., 2011;
Vucic et al., 2013a).
The more recent Awaji criteria, developed to increase diagnostic
sensitivity for MND/ALS, incorporated objective neurophysiologi-
cal biomarkers of LMN dysfunction which included chronic neuro-
genic changes and features of active denervation that also
incorporated the presence of MND fasciculations (de Carvalho
et al., 2008; Costa et al., 2012). Assessment of UMN involvement
however, has remained clinically-based despite the improved diag-
nostic sensitivity using the Awaji criteria. For this reason, there
remains a critical need to develop better in vivo UMN markers to
improve diagnostic certainty that would in turn facilitate enrol-
ment of patients with suspected MND/ALS into appropriate treat-
ment and clinical trials. As such, the current review will provide
an overview of recently developed techniques, including functional
and structural imaging as well as novel electrophysiological
approaches to study the integrity of the corticomotoneuronal (that
part of the corticospinal tract with monosynaptic connections to
spinal cord motor neurons) system in MND/ALS. There is no formal
definition for the ‘‘early stages” of MND with some investigators
suggesting that this may encompass those with minimal disability
as defined by the ALS-FRS score, within a year of symptom onset, or
based on the revised El-Escorial subgroups. In this current review,
‘‘early stages” of MND will be referred to those patients in either
the clinically ‘‘suspected” or ‘‘possible” El-Escorial groups and
especially those without clinically evident UMN signs. A detailed
description of the actual methodology of the techniques discussed
are beyond the scope of this review and readers are encouraged to
refer to referenced papers for such discussion.2. Literature search strategy
A systematic literature review was performed using PubMed
(National Library of Medicine) during the period between 1970
and 2016. The search strategy used the following key words or
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or motor neuron disease, primary lateral sclerosis, upper motor
neuron, corticospinal tract, neuroimaging, imaging, magnetic reso-
nance imaging (MRI), magnetic resonance spectroscopy (MRS), sin-
gle photon emission computed spectroscopy (SPECT), positron
emission tomography (PET), diffusion tensor imaging (DTI), elec-
trophysiology, neurophysiology, F waves, H reflexes, spinal
reflexes, transcranial magnetic stimulation (TMS), cortical
excitability, sensitivity and specificity. Further relevant references
within publications were hand-searched.
3. Clinical neurophysiology
3.1. Spinal reflex changes in MND/ALS
3.1.1. Deep tendon reflexes and the H-reflex
Hyperactive deep tendon reflexes may be masked when there
are severe concomitant LMN changes (Swash, 2012), although
the presence of any deep tendon reflex in a muscle with significant
wasting may be consider as a sign of UMN dysfunction (Simon
et al., 2015). Besides LMN loss, spinal interneurons degenerate
alongside anterior horn cells in MND/ALS (Stephens et al., 2006),
which may contribute to variable segmental excitability of remain-
ing alpha-motoneurons, and in turn prevent the expected hyperac-
tive deep tendon reflex secondary to corticomotoneuronal injury
(Swash, 2012).
The H-reflex represents the neurophysiological correlate of the
deep tendon reflex and is a monosynaptic reflex evoked by stimu-
lation of Ia sensory afferents that project on homonymous
motoneurons. At the most simple level, presence of an H-reflex
in a clinically wasted and weak muscle, is clear evidence of upper
motor neuronal dysfunction, a finding that will facilitate an early
diagnosis of MND/ALS. The H-reflex has been used to assess seg-
mental motoneuronal excitability in a variety of neurological dis-
eases usually through measurement of Hmax/Mmax ratio, or the
ratio of the amplitude of the maximal H-reflex relative to the max-
imal compound muscle action potential (CMAP, M-wave) ampli-
tude (Pierrot-Deseilligny and Burke, 2012). Typically Hmax/Mmax
is increased in disorders characterised by spasticity and hyper-
reflexia (Misiaszek, 2003). Of interest, MND/ALS patients do not
demonstrate significantly higher Hmax/Mmax relative to normal
controls, despite the presence of clinical UMN signs (Raynor and
Shefner, 1994; Mazzini et al., 1997), although increased Hmax/Mmax
did significantly correlate with hyperreflexia and the Babinski sign
(Mazzini et al., 1997).
This unexpected finding was further explored in recent
studies of the H-reflex in MND/ALS patients (Simon et al., 2015).
Hmax/Mmax was similar between MND/ALS patients and healthy
subjects. Like previous studies, Hmax/Mmax did correlate with a
composite clinical score of clinical UMN signs. However, Hmax/Mmax
was affected by the position of the H reflex recruitment curve
relative to the M wave recruitment curve. It was inferred that
preferential loss of fast-conducting motoneurons in MND/ALS
alters the dynamics of H-reflex recruitment and attenuates the
measurable Hmax, hence reducing Hmax/Mmax (Simon et al., 2015).
An alternative measure, Hh/Mh, is independent of the effects of
collision of antidromic and orthodromic impulses generated by
direct nerve stimulation and the descending H reflex respectively.
Hh and Mh are calculated from the slope angle of the earliest rising
phase of the H- and M-wave recruitment curves. It is generally
accepted that recruitment of the H-reflex follows the size principle,
such that the initial phase of the H-reflex recruitment curve is
formed from activation of smaller calibre motor neurons
(Buchthal and Schmalbruch, 1970). Conversely, the largest calibre
motor neurons have the lowest threshold to electrical stimulation
(Feiereisen et al., 1997), and as such the earliest portion of theM-wave recruitment curve is comprised of potentials produced
by the largest calibre motor axons. As such, Hh andMh are indepen-
dent of the artifactual influence of collision where Hmax and Mmax
are not.
The ratio of the recruitment slope of the H reflex and M wave
(equivalent to Hh/Mh) is increased in spastic limbs (Funase et al.,
1994, 1996; Higashi et al., 2001). Similarly, in MND/ALS patients,
Hh/Mh was increased relative to healthy subjects and was closely
correlated with clinical UMN signs (Simon et al., 2015). As such,
Hh/Mh may be a more suitable measure of segmental motoneuronal
hyperexcitability in MND/ALS than the more traditional Hmax/Mmax
(Fig. 1).
3.1.2. Plantar reflexes
It has been estimated that only 30% of MND/ALS patients
demonstrate an extensor plantar response (Baek and Desai,
2007). However, electrophysiological assessment of the plantar
reflex in MND/ALS patients shows a typical ‘extensor reflex’ pat-
tern with activation of extensor hallucis longus, extensor digito-
rum longus and tibialis anterior superimposed on tonic
activation of flexor hallucis brevis irrespective of whether the clin-
ical response was extensor or flexor (Landau and Clare, 1959). In
addition, studies of patients with unexpectedly absent extensor
plantar responses despite the presence of other UMN signs indicate
that an extensor plantar response may only be evident if the
intraspinal pathways of the flexion reflex is intact (Van Gijn,
1978). Thus the absence of extensor plantar responses in
MND/ALS may reflect injury to the spinal segmental connections
contributing to the extensor plantar response (Swash, 2012).
3.1.3. Other spinal interneuronal networks
Neurophysiological studies of spinal interneuronal function
other than the H reflex are less extensive in MND/ALS. However,
analysis of spinal interneuronal dysfunction may provide further
insights into mechanism of LMN loss.
Excitability of the F-wave is influenced by UMN dysfunction
(Drory et al., 1993). In MND/ALS, F-wave excitability has been mea-
sured using persistence and the ratio of the F-wave and corre-
sponding compound muscle action potential amplitude (F/M
ratio) (Drory et al., 2001). While F-wave persistence diminishes
with advancing disease (de Carvalho et al., 2003), the F/M ratio
increases in MND/ALS relative to controls, although these changes
are not influenced by the degree of clinical UMN involvement
(Drory et al., 2001). However, increase in the F/M ratio is not
restricted to UMN lesions, as it is also seen in polyneuropathy
(Fisher, 1988), limiting its value as a measure of UMN dysfunction.
There is reduced presynaptic inhibition in MND/ALS (Bour et al.,
1991; Lee et al., 2014), consistent with findings in patients with
brain or spinal cord lesions producing spasticity (Hultborn et al.,
1987). However, reciprocal inhibition, a marker of Renshaw cell
interneuronal function in the spinal cord, was significantly reduced
in MND/ALS patients relative to normal controls, opposite to what
was identified in patients with spinal cord injury (Raynor and
Shefner, 1994). These findings suggest that interneuronal influ-
ences in MND/ALS are more complex than those seen in more focal
lesions (Turner et al., 2012).
3.2. Transcranial magnetic stimulation
Traditional approaches such as nerve conduction studies (NCS)
and EMG provide a quantitative measure of LMN loss such as
CMAP amplitude and motor unit recruitment although quantifying
UMN loss remains more difficult. An important focus in the devel-
opment of a neurophysiological biomarker of MND/ALS has been
the identification of cortical hyperexcitability and the quantifica-
tion of UMN dysfunction (Turner et al., 2009). Transcranial
Fig. 1. Changes in the H-reflex pathway in ALS patients. Comparison of the slope angle of the H-reflex recruitment curve (Hh), the slope angle of theM-wave recruitment curve
(Mh), their ratio Hh/Mh (slope ratio), and Hmax/Mmax between ALS (black filled bar), healthy control (open bar) and UMN disease control groups (grey filled bar). Hh/Mh was
significantly increased in the ALS and disease control groups (A), and Hmax/Mmax was increased in disease controls but similar between healthy control and ALS groups.Mh was
reduced in the ALS group but Hh did not differ significantly between groups (B). The UMN Score was associated with changes in both Hh/Mh (C) and Hmax/Mmax (D) in ALS
patients with this relationship strongest for Hh/Mh. Illustrative M-recruitment curves in ALS patients are depicted (E) to illustrate the relationship between Mh, Mthresh and
clinical UMN signs. Patient 22 (lower limb onset, filled circles) displayed prominent UMN signs in the displayed lower limb (UMNS 5 out of 6), and bothMh and Mthresh were
relatively low. Patient 15 (upper limb onset, open triangles) did not display clinical UMN signs on examination (UMNS 0 out of 6) andMh and Mthresh were relatively high. A
healthy control subject is superimposed (open circles; Mthresh = 6.3 mA, Mh = 47.6). Mh was strongly correlated with M threshold (F) in ALS patients, which in turn was
correlated with clinical UMN signs. Reproduced with permission (Simon et al., 2015).
2646 W. Huynh et al. / Clinical Neurophysiology 127 (2016) 2643–2660magnetic stimulation (TMS) techniques have gained credibility as a
clinical tool to investigate the integrity of the corticomotoneuronal
system in MND/ALS. Single, paired, and triple-pulse TMS tech-
niques have all been utilised, with such parameters as motor
threshold (MT), central motor conduction time (CMCT), cortical
silent period (CSP), intracortical inhibition and facilitation, taken
to reflect corticomotoneuronal function (Vucic and Kiernan,
2013). Features of cortical hyperexcitability were characterisedby functional abnormalities, including reduced short-interval
intracortical inhibition and CSP duration, as well as an increase
in intracortical facilitation, along with inexcitability in the motor
cortex (Grieve et al., 2015).
Moreover there were significant bilateral TMS abnormalities
evident in the MND/ALS cohort at an early stage of the disease pro-
cess, in keeping with previous studies reporting that functional
abnormalities of the motor cortex are an early and specific feature
Fig. 2. Paired-pulse subthreshold conditioning TMS (a) An illustrative example
disclosing short-interval intracortical inhibition (SICI) and intracortical facilitation
(ICF) in a healthy control. SICI was absent whilst ICF was increased in an ALS
patient. (b) Group data revealed a significant reduction of SICI and increase of ICF in
ALS. Reproduced with permission (Geevasinga et al., 2014).
W. Huynh et al. / Clinical Neurophysiology 127 (2016) 2643–2660 2647of MND/ALS, preceding the development of LMN dysfunction
(Vucic and Kiernan, 2006; Vucic et al., 2008, 2013c; Geevasinga
et al., 2014; Grieve et al., 2015; Menon et al., 2015b).
3.2.1. Single-pulse TMS
The time interval between stimulation of the motor cortex and
onset of the resultant motor evoked potential (MEP) response from
the arrival of corticospinal volley at the spinal motor neuron, is ter-
med the central motor conduction time (CMCT) (Vucic and
Kiernan, 2013). Multiple factors contribute to the CMCT including
time to activate the corticospinal cells, conduction time of the
descending volley down the corticospinal tract, synaptic transmis-
sion and activation of spinal motor neurons (Vucic et al., 2013c).
CMCT is reported to be prolonged in a variable proportion of
MND/ALS patients (16–100%) (Mills and Nithi, 1998; Miscio
et al., 1999; Schulte-Mattler et al., 1999; Triggs et al., 1999;
Pouget et al., 2000; Kaufmann et al., 2004; Vucic and Kiernan,
2013), with a specificity of 38% (Kaufmann et al., 2004). Addition-
ally, CMCT abnormalities in patients without clinically overt UMN
involvement had a sensitivity of 50–71% (Miscio et al., 1999;
Schulte-Mattler et al., 1999). Although the mechanisms underlying
prolongation of the CMCT in MND/ALS remain to be fully eluci-
dated, an increased desynchronization of corticomotoneuronal vol-
leys, secondary to axonal loss, as well as axonal degeneration of the
fastest conducting corticomotoneuronal fibres have been proposed
as likely mechanisms (Eisen et al., 1996; Vucic and Kiernan, 2013;
Vucic and Kiernan, 2013b). It should also be noted that CMCT cal-
culations are associated with technique-dependent variations that
likely account for the large discrepancies in sensitivity reported by
previous studies.
Corticomotor threshold or the resting motor threshold (RMT),
reflects the ease with which corticomotoneurons are excited and
the density of UMN projections onto motor neurons (Rossini
et al., 1999) with the highest projections for intrinsic hand muscles
being reflected in the lowest motor thresholds for these muscles
(Vucic and Kiernan, 2013). RMTs are influenced by the glutamater-
gic neurotransmitter system, through a-amino-3-hydroxy-5-
methyl-4-isoxazoleproprionic acid (AMPA) receptors, whereby
excessive glutamate activity reduces MTs as well as being modu-
lated by sodium channel blockers (Vucic et al., 2013b). RMT in
MND/ALS varied between studies but in general appeared to be
lower early on in the disease course and higher or even inexcitable
as disease progressed (Eisen et al., 1993; Mills and Nithi, 1997;
Triggs et al., 1999; Grieve et al., 2015). Reduced RMT may be mod-
ulated by increased glutamate excitation, reduced gamma-
Aminobutyric acid (GABA) inhibition or a combination of both
(Vucic et al., 2013b). Given that motor threshold may be modu-
lated by glutamate activity, the finding of reduced motor threshold
early in the disease course of MND/ALS may support a dying-
forward process, whereby cortical hyperexcitability underlies the
development of progressive neurodegeneration via glutamate tox-
icity (Vucic and Kiernan, 2013). The motor cortex is inexcitable in
about 20% of patients and appeared to be a finding late in the dis-
ease course (Grieve et al., 2015), as well as being a relatively fre-
quent early finding in patients with PLS (Geevasinga et al., 2015b).
The interruption of voluntary electromyography (EMG) activity
in the target muscle following stimulation of the motor cortex is
referred to as the cortical silent period (CSP) (Cantello et al.,
1992). Mechanisms underlying the generation of the CSP are com-
plex but primarily mediated by activation of cortical inhibitory
neurons, through long-lasting inhibitory postsynaptic potentials,
acting via GABA-B receptors (Ziemann et al., 1993; Vucic and
Kiernan, 2013). However, a contribution from spinal mechanisms
has also been suggested for early cortical silent period segments
(Cantello et al., 1992; Vucic and Kiernan, 2013). The CSP duration
has been reported to show a reduction or absence in patients withMND/ALS across all phenotypes (Uozumi et al., 1991; Desiato and
Caramia, 1997; Pouget et al., 2000; Vucic and Kiernan, 2006, 2013;
Grieve et al., 2015) and is reported in both sporadic and familial
MND/ALS, with the degree of duration reduction being most
prominent early in the disease course (Prout and Eisen, 1994;
Vucic and Kiernan, 2006, 2013; Vucic et al., 2008). Of relevance,
this reduction in CSP duration appeared specific for MND/ALS,
being normal in mimic disorders such as Kennedy’s disease,
acquired neuromyotonia, and distal hereditary motor neuronopa-
thy with pyramidal features (Vucic and Kiernan, 2008; Vucic
et al., 2010a,b, 2011; Menon et al., 2015a). The CSP duration reduc-
tion in MND/ALS is likely to represent a combination of decreased
corticomotoneuronal drive and reduced GABAergic inhibition, due
to either degeneration of inhibitory interneurons or dysfunction of
GABAB-mediated receptor inhibition (Vucic and Kiernan, 2013).
Absent or prolonged ipsilateral CSP duration has also been identi-
fied in the early stage of MND/ALS, potentially representing dys-
function of inhibitory transcallosal neurons, a notion supported
by recent MRI studies (Turner et al., 2009; Vucic et al., 2013).3.2.2. Paired-pulse TMS
Cortical excitability may be assessed effectively using a paired-
pulse technique, in which a conditioning stimulus is utilised to
modulate the effect of a second test stimulus. A potential limitation
of the original ‘‘constant stimulus” paired-pulse TMS method was
the significant variability in the MEP amplitude with consecutive
stimuli (Kiers et al., 1993), resulting in fluctuations in the resting
threshold of cortical neurons. For this reason, to ensure validity
Fig. 3. (a) Averaged short-interval intracortical inhibition (SICI), between interstimulus interval (ISI) 1–7 ms, was significantly reduced in amyotrophic lateral sclerosis (ALS).
(b) The reduction of averaged SICI was comparable in Awaji subgroups. Peak SICI at ISI (c) 1 ms and (d) 3 ms was significantly reduced in Awaji subgroups. ⁄⁄⁄⁄P < 0.0001.
Reproduced with permission (Geevasinga et al., 2014).
Fig. 4. (a) Short-interval intracortical inhibition (SICI) was significantly reduced in
amyotrophic lateral sclerosis (ALS) when compared to non-ALS syndrome (NALS)
patients and controls. (b) Averaged SICI, between interstimulus intervals (ISI)
1–7 ms, was significantly reduced in ALS patients compared to NALS patients and
controls. However, SICI was comparable between NALS patients and controls.
⁄⁄⁄⁄P < 0.001. Reproduced with permission (Vucic et al., 2011).
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each conditioning-test stimulus interval. In order to overcome this
limitation, a novel threshold tracking technique was recently
developed, in which a constant target MEP response is tracked by
a test stimulus, utilising a range of different conditioning-test para-
digms (Fisher et al., 2002; Vucic et al., 2006). Using this technique,
applying a subthreshold conditioning stimulus (set to 70%RMT) at
predefined time intervals prior to a suprathreshold test stimulus
has been used to investigate short-interval intracortical inhibition
(SICI) and intracortical facilitation (ICF) (Kujirai et al., 1993; Vucic
et al., 2006).
SICI, a biomarker of inhibitory GABAergic cortical interneuronal
function, was significantly reduced or absent in MND/ALS patients
compared to controls and there was no significant difference in the
degree of reduction between the right and left sides, between
patients with less severe versus more prominent LMN dysfunction,
or between differing sites of onset (Turner et al., 2009; Vucic and
Kiernan, 2013; Geevasinga et al., 2014; Grieve et al., 2015)
(Fig. 2). The reduction in SICI has been widely documented in both
sporadic and familial forms of MND/ALS and appears to be an early
feature in sporadic MND/ALS (Hanajima et al., 1996; Yokota et al.,
1996; Ziemann et al., 1997; Zanette et al., 2002b; Vucic and
Kiernan, 2006, 2013; Vucic et al., 2008, 2010b,c; Geevasinga
et al., 2015a). With either abnormal SICI or inexcitable motor
cortex, the threshold-tracking TMS technique was shown to have
a sensitivity of 73.21% and a specificity of 80.88% (Menon et al.,
2015a) and there were no differences in the sensitivity of the
technique between patients with or without UMN signs
(Geevasinga et al., 2014; Menon et al., 2015a). Furthermore, an
absent SICI demonstrated a sensitivity of 97% (Vucic et al.,
2013b). When the established cut-off value of SICI (<5.5%) (Vucic
et al., 2011) was combined with parameters such as prolonged
CMCT or inexcitable motor cortex, TMS abnormalities were evident
in 77% of MND/ALS patients with frequency of abnormalities sim-
ilar across Awaji diagnostic groups (Geevasinga et al., 2014). And
the presence of such TMS abnormalities resulted in 88% of Awaji
possible patients being reclassified as Awaji probably/definite(Geevasinga et al., 2014). Specifically, 56% of Awaji possible
patients had abnormally reduced SICI (Geevasinga et al., 2014)
(Fig. 3). Using the threshold-tracking technique, SICI abnormalities
seem to be the most robust diagnostic variable suggestive of UMN
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et al., 2015a,b).
Abnormalities derived from the use of this technique may
potentially be limited by the end-point result obtained from the
target muscle studied which in most cases, have been an intrinsic
hand muscle. However, previous studies have also identified simi-
lar abnormalities in SICI from abductor pollicis brevis (APB) mus-
cles in patients with the flail-leg variant of MND/ALS where the
disease is confined to the lower limbs only (Menon et al., 2016).
In addition, combining TMS with novel imaging studies have also
revealed multiple areas of cortical abnormalities beyond those of
the motor cortex (Huynh et al., 2013a,b,2016; Grieve et al.,
2015). Reduction of SICI as occurs in MND/ALS is mediated by a
loss of GABA-secreting inhibitory cortical interneurons (Vucic
and Kiernan, 2013), a finding supported by neuropathological stud-
ies disclosing loss of parvalbumin positive inhibitory interneurons
in MND/ALS (Nihei et al., 1993). These results suggest that the
abnormalities in cortical excitability obtained from a target hand
muscle reflect a more widespread abnormality not only in the
motor cortex itself but also in other regions of the brain. In addi-
tion, a contributory role for a glutamate-mediated excitotoxic
mechanism was also suggested by partial restoration of SICI in
patients with MND/ALS who were treated with the glutamate
antagonist, riluzole (Stefan et al., 2001; Vucic et al., 2009, 2013a).
Intracortical facilitation, a potential biomarker of cortical glu-
taminergic function, has been reported to be significantly
increased in MND/ALS patients (Vucic and Kiernan, 2013; Grieve
et al., 2015) (Fig. 1) although not in other studies (Zanette et al.,
2002a,b). The use of cortical excitability testing using this tech-
nique may be able to unveil upper motor neuron involvement in
MND/ALS patients particularly those phenotypes without clinically
evident upper motor neuron signs on examination such as the flail
arm variant of MND/ALS (Vucic and Kiernan, 2007). When com-
pared to the Awaji criteria alone, an extra 34% of ALS patients could
be diagnosed with ALS at initial assessment when using the thresh-
old tracking TMS parameters combined with clinical and conven-
tional electrophysiological assessments (Menon et al., 2015a). Of
further relevance, the technique enabled reliable distinction
between MND/ALS and other neurological conditions mimicking
the disorder such as in Kennedy’s disease, spinal muscular atrophy,
peripheral nerve hyperexcitability disorders, multifocal motor
neuropathy, Hirayama disease, lead neuropathy, CIDP, hereditary
motor neuropathy with pyramidal features, and hereditary spastic
paraparesis (Vucic and Kiernan, 2008, 2010a,b; 2011; Farrar et al.,
2012) (Fig. 4).
3.2.3. Triple stimulation technique
The triple stimulation technique (TST) was developed as a
means of increasing the sensitivity of TMS techniques in detecting
corticomotoneuronal dysfunction. The TST is a collision technique,
whereby the degree of MEP desynchronization (which normally
occurs with single cortical stimulus) may be suppressed
(Magistris et al., 1998, 1999; Vucic et al., 2013b). Using TST, mea-
surement of the evoked response over a hand muscle is performed
following stimulation of motor cortex, wrist and Erb’s point in suc-
cession. This complex technique is performed by first delivering a
high-intensity magnetic stimulus to motor cortex followed by
supramaximal electrical stimulation of the peripheral nerve sup-
plying the target muscle at the wrist such that the descending cor-
ticomotoneuronal volley is ‘collided’ out by the antidromic action
potentials. Collision takes place along the proximal segment of
the peripheral nerve at the upper arm. A third stimulus is subse-
quently delivered to Erb’s point (axilla) after an appropriate delay,
eliciting a highly synchronised motor response in those fibres in
which the collision had occurred. The amplitude and area of this
test CMAP response are compared with the response induced bythe conditioned TST paradigm (Erb’s point-wrist–Erb’s point stim-
ulation) yielding an amplitude ratio of >93% and area ratio of >92%
in healthy controls (Magistris et al., 1998, 1999; Vucic et al.,
2013b). The derived TST amplitude ratio allows the estimate of a
proportion of surviving corticospinal motor neurons. In MND/
ALS, the TST has been suggested to be sensitive at detecting sub-
clinical UMN dysfunction with an apparent 100% sensitivity in
those with suspected or possible MND categories (Komissarow
et al., 2004), thereby enabling an earlier diagnosis of MND/ALS
(Kleine et al., 2010). However, an overall sensitivity was found to
be of around only 54% (Furtula et al., 2013), as there were about
48% of patients with clinically apparent UMN and normal ratios.
Furthermore, the test was limited in patients with significant
LMN loss (Rosler et al., 2000), suggesting that the test may be use-
ful primarily in the early stages of the disease when there are sub-
clinical UMN signs. The TST amplitude ratio was smaller in MND/
ALS patients with pure UMN or mixed UMN and LMN involvement
compared to those without clinical UMN signs (Rosler et al., 2000).
It was also able to distinguish between certain mimic disorders
such as inclusion body myositis and other peripheral nerve disor-
ders (Kleine et al., 2010). The triple stimulation technique offers
promise to increase the sensitivity to UMN lesions but it is not
yet being used routinely as it is difficult to apply.
Over the years, paired-pulse TMS and in particular assessment
of SICI has emerged to be the more favoured and accurate diagnos-
tic technique over that of the traditional single-pulsed techniques.
Triple-stimulation techniques offer a promising novel approach to
enhance the diagnostic sensitivity for detecting subclinical UMN
involvement but the patient numbers studied thus far are very
small and further larger-scale studies are required to establish its
potential clinical utility in MND/ALS. Until then, the use of abnor-
malities in SICI and an inexcitable motor cortex would offer the
most valuable approach in disclosing UMN dysfunction in MND/
ALS patients (Burrell et al., 2011; Vucic and Kiernan, 2013;
Geevasinga et al., 2014; Menon et al., 2014, 2015a).
3.3. Peristimulus time histograms
Peristimulus time histograms (PSTH) can be used to assess the
integrity of the corticomotoneuronal system (Weber and Eisen,
2000) whereby the modulation in firing of a single motor unit in
response to a stimulus can be assessed (Eisen and Weber, 2001;
Vucic and Kiernan, 2013). The primary peak (PP) measure changes
in the firing probability of a voluntarily activated motor unit sub-
jected to a series of transcranial magnetic stimuli (Eisen and
Weber, 2000; Weber and Eisen, 2000). In healthy controls, a well
synchronised primary peak was evident at a latency of approxi-
mately 20–30 ms (Vucic et al., 2013b). PSTHs have shown a variety
of abnormalities in MND/ALS that suggest there is a supraspinal
defect, which is pre-synaptic to the spinal motor neuron. The major
abnormality observed in MND/ALS patients was a desynchronised,
complex, primary peak that had an increased duration and
delayed. This result was best explained by an increase in the repet-
itive firing of the corticomotoneuron associated with greater tem-
poral dispersion of the descending cortical volley (Awiszus and
Feistner, 1993, 1995; Mills, 1995; Eisen et al., 1996; Nakajima
et al., 1997; Eisen and Weber, 2000, 2001; Weber and Eisen,
2000; Weber et al., 2000). In addition, the amplitude of the primary
peak was increased and additional subcomponents were evident,
all of which are suggestive of corticomotoneuronal hyperexcitabil-
ity (Eisen et al., 1999). An argument in favour of a supraspinal ori-
gin for abnormal PSTH results in MND/ALS was suggested by the
lack of abnormalities demonstrated in Kennedy’s disease, which
affect only the LMNs (Eisen and Weber, 2000) (Fig. 5).
With increased disease duration, progressive desynchronization
occurs in PPs, characterised by an increased number of excess bins
Fig. 5. Peristimulus time histograms in normal controls (a) and patients with Kennedy’s disease (b) compared to that in ALS (c). Reproduced with permissions (Eisen and
Weber, 2000).
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time have been explained by the activation of slow-conducting
pathways and progressive loss of fast monosynaptic pathways
from pyramidal Betz cells (Weber and Eisen, 2000). The desynchro-
nization is thought to reflect repetitive firing of the cortical colony,
which in part may be due to glutamate excitotoxicity (Eisen and
Weber, 2000).
The sensitivity of PSTHs in MND/ALS has not been established
but there is good correlation between PP abnormalities and UMN
signs without correlation with LMN signs (Weber and Eisen,
2000). However, most PP abnormalities are not specific to MND/
ALS and can be observed in other central nervous system disorders
such as stroke and MS although the double PP appears typical to
MND/ALS reflecting activation of the slow-conducting pathways
(Weber and Eisen, 2000).3.4. Beta-band intermuscular coherence
Rhythmic activity can be recorded from the motor cortex in the
alpha (15–30 Hz) and beta (8–12 Hz) frequency bands. Intermus-
cular coherence during a sustained muscle contraction is depen-
dent on supraspinal structures including the corticospinal tract. Arecent study using this technique demonstrated that the beta-
band coherence was observed in all healthy controls as well as
patients with PMA where there is an intact UMN integrity and
not substantially altered by loss of LMNs. Furthermore, the results
were abnormal in all patients with PLS and hence suggested that
assessment using this technique could provide information regard-
ing upper motor neuron involvement and facilitate a more defini-
tive diagnosis of MND/ALS in patients with otherwise subclinical
UMN signs (Fisher et al., 2012).4. Neuroimaging
Previously, the World Federation of Neurology stated that there
was no role for neuroimaging in confirming the diagnosis of MND/
ALS (Brooks, 1994), and conventional imaging methods have been
used primarily to exclude other potential diagnoses that may be
mimicking the disorder, particular in those with clinically probable
or possible disease. In more recent times however, advanced neu-
roimaging techniques have facilitated investigation of the central
nervous system for atrophy and alterations in microstructure, bio-
chemistry, neural networks, metabolism and neuronal receptors
that may occur in patients with MND/ALS as means to identify
Fig. 6. Cerebral MRI of a patient with ALS demonstrating (a, b) signal hyperintensities along the corticospinal tract (arrows). Reproduced with permission (Rocha and Maia
Júnior, 2012).
Fig. 7. Voxel-based intensitometry reflects disease severity in the corticospinal tract, transcallosal fibres and brainstem. Whole brain group-mean of T1 images projected on
generic brain (a, b) and Maximum Intensity Projection of significantly different regions (d, e). The extent of MRI intensity change in ‘low’ disability group (a, d) is significantly
less widespread than in the ‘high’ disability group (b, e). Inference was done using Threshold Free Cluster Enhancement (10,000 permutations) und Family-wise error rate
correction for multiple comparisons. Colour spectrum giving p-value indication (c). Reproduced with permission (Hartung et al., 2014).
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stages of disease (Foerster et al., 2013b).
4.1. MRI
4.1.1. Structural MRI
Conventional MRI have identified hypointensities over the
motor cortices in patients with MND/ALS whilst hyperintense sig-
nalling was observed on T2-weighted images involving the corti-
cospinal tracts (CST) (Peretti-Viton et al., 1999; Agosta et al.,2010a; Huynh et al., 2010; Rocha and Maia Júnior, 2012), but nei-
ther were specific to the disease itself being also present in other
neurodegenerative disorders as well as older age controls. More
specifically, abnormal signal intensity in the posterior third of
the posterior limb of the internal capsule correlated with degener-
ation of the corticospinal tract on histopathology (Yagishita et al.,
1994). Hyperintensities involving the CST was associated with
low sensitivity (640%) and specificity (670%) (Fig. 6), and the sen-
sitivity may be lower in patients with less severe motor symptoms
or in the early stages of the disease (Chan et al., 2003). This is
2652 W. Huynh et al. / Clinical Neurophysiology 127 (2016) 2643–2660despite degeneration of the entire CST reportedly occurring in
approximately 47% of autopsy specimens from patients with
MND (Brownell et al., 1970). In addition, the CST signal changes
did not appear to correlate with clinical scores (Agosta et al.,
2010a). The combination of these two findings however may be
more specific for MND/ALS (Goodin et al., 1988; Luis et al., 1990;
Oba et al., 1993; Shiozawa et al., 2000).
More advanced techniques based on high resolution T1 images
such as volume-based morphometry (VBM) measures relative grey
and white matter volumes in specific brain regions whilst
surfaced-based morphometry (SBM) measures cortical thickness.
White matter changes are more reliably detected using the
recently developed VBM derivative voxel-based intensitometry
(Hartung et al., 2014) (Fig. 7). Most VBM analyses have demon-
strated widespread grey matter atrophy involving the motor cortex
extending into the frontal and parietal regions in patients with
MND/ALS whilst SBM show consistent reductions in cortical thick-
ness in MND/ALS motor cortices with progressive thinning over
time (Grosskreutz et al., 2006; Foerster et al., 2013b; Zhu et al.,
2015). Some studies have proposed such cortical thinning as a
potential early biomarker of UMN dysfunction (Verstraete et al.,
2012; Mezzapesa et al., 2013; Thorns et al., 2013; Walhout et al.,
2015). In other studies, bitemporal cortical thinning were evident
in MND/ALS patients and independent of functional abnormalities
with 56% of motor cortices analysed revealing significant thinning
below the previously established diagnostic cut-off values
(<2.48 mm) (Grieve et al., 2015; Walhout et al., 2015). Correlation
with disease severity is low in grey matter analyses, possibly due
to the high physiological inter-individual anatomical variability
of gyri (Verstraete and Foerster, 2015). White matter signal
increase in VBI, however, correlates linearly with ALSFRS-R reduc-
tion in large portions of the CST from subcortical regions through
the internal capsule into the brainstem (Hartung et al., 2014).
VBM and SBM studies have also demonstrated reduction in
frontotemporal cortical regions that correlated with cognitive
impairment in MND/ALS patients, in that those with cognitive
impairment and patients with the ALS–FTD overlap syndrome
showing the greatest change (Abrahams et al., 2005; Chang et al.,
2005; Grosskreutz et al., 2006; Murphy et al., 2007; Agosta et al.,
2012).
Despite evidence of regional atrophy identified on VBM in the
abovementioned studies, other investigators have not observed
such differences (Kiernan and Hudson, 1994; Ellis et al., 2001;
Abrahams et al., 2005; Mezzapesa et al., 2007), and combined with
its limited sensitivity, render the utility of this MRI technique for
detecting UMN dysfunction in MND patients limited at present.
Part of the reason for this may be the small and heterogeneous
patient groups together with methodological differences or
limitations. Moreover, longitudinal studies in MND patients areFig. 8. Diffusion Tensor Imaging. TBSS P value maps fully corrected for multiple compar
anisotropy (FA). Results displayed at significant levels (p < 0.05, fully corrected for multip
the mean FA image derived from all participants. Major fibre tracts as determined by
corrected differences between patients and controls (p < 0.05). Locations of images in s
(Chapman et al., 2014).challenging as progressive bulbar and respiratory weakness pose
a challenge to serial scanning.
The use of diffusion tensor imaging (DTI) measure water move-
ment within intact neuronal pathways and is highly anisotropic
(i.e., non-random) with parameters such as reduced fractional ani-
sotropy (FA) and, less commonly, increased mean diffusivity being
potential surrogate markers for loss of neuronal integrity within
white matter tracts (Turner et al., 2009; Simon and Kliot, 2014).
MRI studies using DTI in MND/ALS patients have demonstrated
reduced FA in the CST, with the lowest values observed in the
PLS phenotype and more modest reductions in ALS and least with
PMA subgroups (Abe et al., 2004; Sach et al., 2004; Thivard et al.,
2007; Iwata et al., 2008, 2011; Sage et al., 2009; Agosta et al.,
2010b; Cosottini et al., 2010; Filippini et al., 2010; Chapman
et al., 2014). More specifically, FA values in the CST appear to be
correlated with UMN scores (Wong et al., 2007; Sage et al., 2009)
and FA was also reduced in several frontal white matter regions
that correlated with cognitive scores and executive function (Abe
et al., 2004; Sach et al., 2004; Sage et al., 2009; Keil et al., 2012).
Others however, have observed FA values in the posterior limb of
the internal capsule of PMA patients to be similar to those of ALS
patients with obvious UMN signs on initial assessment (Graham
et al., 2004; Sach et al., 2004), and the eventual development of
clinical UMN features (Sach et al., 2004). This suggests a potential
clinical utility for its use to detect subclinical UMN features in sus-
pected patients, although conflicting data exists from other studies
(Cosottini et al., 2005). Bulbar-onset patients also appear to have
the more marked reductions in FA (Turner and Kiernan, 2012).
Pooled sensitivity and specificity for DTI in the assessment of
changes observed in MND patients was found to be 68% and 73%
respectively (Foerster et al., 2013a). The spreading of FA reduction
into frontal regions and the cerebellum (Keil et al., 2012) in longi-
tudinal studies also correlated with ALSFRS-R, disease duration and
disease progression (Jacob et al., 2003; Agosta et al., 2009; Zhang
et al., 2011; Keil et al., 2012). In addition, FA was also found to
be reduced in the corpus callosum of patients with MND/ALS and
particular, the middle posterior body of the corpus that connects
the motor and motor association cortices thus supporting the
hypothesis that disease propagates along structural connections
(Sach et al., 2004; Filippini et al., 2010; Bak and Chandran, 2012;
Foerster et al., 2013b; Chapman et al., 2014) (Fig. 8).
Magnetic transfer imaging (MTI) is based on the exchange of
magnetisation between spins in two proton pools: bound immo-
bile protons associated with macromolecules (such as myelin)
and free mobile protons associated with free water. The technique
can demonstrate presence of structural changes in tissue associ-
ated with disease, even in the absence of changes observed in other
sequences (Rocha and Maia Júnior, 2012c). The use of MTI in
detecting structural changes involving the CST in MND patientsisons of voxel-wise differences between patients and healthy controls for fractional
le comparisons) in Montreal Neurological Institute (MNI) standard space overlaid on
TBSS are displayed in green. Red-yellow clusters indicate locations of significant
tandard space are X = 1, Y = 17, Z = 19, MNI mm. Reproduced with permission
Fig. 9. Proton magnetic resonance spectroscopy (MRS) in an ALS patient (a) compared to control patient (b) demonstrated reduction in the NAA peak in ALS. Reproduced with
permission (Han and Ma, 2010).
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magnetisation transfer contrast (T1 SE MTC), with impressive sen-
sitivity (80%) and specificity (100%) (da Rocha et al., 2004; Rocha
and Maia Júnior, 2012). In addition, the sequence is fast and simple
to acquire, and shown to be particularly useful in the early course
of the disease to detect signal hyperintensity in the CST. The
changes however were overrepresented in the cohort of MND
patients with overt clinical UMN features and seldom in those with
LMN predominant phenotypes such as PMA rendering the tech-
nique of limited utility in detecting subclinical UMN dysfunction
(Carrara et al., 2012).
4.1.2. Magnetic resonance spectroscopy
Proton magnetic resonance spectroscopy (MRS) measure regio-
nal biochemistry in vivo and can detect proton-containing metabo-
lites including N-acetyl aspartate (NAA), choline, and creatine (Cr)
(Kaufmann and Mitsumoto, 2002; Kaufmann et al., 2004). NAA
occur in neurons but not in glia (Kaufmann and Mitsumoto,
2002) and is marker of neuronal integrity or neuronal loss or dam-
age depending on whether expressed as ratio to creatine or choline
(respectively) (Turner et al., 2009).
Studies using MRS in MND/ALS patients have described a signif-
icant decrease in the ratio of NAA to creatine or choline in the
motor cortex and other regions of the CST (Pioro et al., 1994;
Giroud et al., 1996; Block et al., 1998; Rooney et al., 1998; Pohl
et al., 2001a; Kaufmann et al., 2004) suggesting reduced neuronal
integrity in the motor cortices (Foerster et al., 2013b), although
at what stage of the disease process these changes become evi-
dence remains conflicting (Figs. 9 and 10). Less dramatic changes
were also observed in the bilateral frontal and parietal regions
(Rule et al., 2004). Such levels of NAA were found to decrease lon-
gitudinally as disease progresses (Rule et al., 2004; Unrath et al.,
2007; van der Graaff et al., 2010) but improved following institu-
tion of Riluzole (Kaufmann et al., 2004). The changes were also
observed to correlate with disease severity, extent of UMN signs
and clinical scores although these were based on cross-sectional
studies (Agosta et al., 2010a). The mean decrease in NAA varied
between studies and reportedly between 8% and 56% (Kaufmann
and Mitsumoto, 2002) with one study suggesting a NAA/Cr ratio
cut-off of 2.5 for normal values (Chan et al., 1999). This abnormal-
ity observed in MRS has been reported across all MND/ALS pheno-
types with similar reductions observed in ALS and PLS and lesspronounced changes with PMA (Gredal et al., 1997; Mitsumoto
et al., 2007). Furthermore, the reductions appeared more dramatic
in MND/ALS patients with bulbar onset compared to limb onset
(Ellis et al., 1998). Of particular relevance, abnormal MRS was
demonstrated in a small number of autopsy cases without signifi-
cant loss of Betz cells, suggesting that MRS may be able to detect
UMN changes before Betz cell loss is visible using conventional
stains or that sampling of cortex may miss affected areas
(Kaufmann et al., 2004). Taken together, this suggests that the
use of NAA reduction observed in MRS may be able to uncover sub-
clinical UMN involvement in patients with MND/ALS although the
results are more likely to be abnormal later on in the disease
course rather than in the early stages. Moreover, MRS was able
to distinguish MND/ALS from mimics such as SMA without UMN
signs which showed no changes in the NAA ratio (Pioro et al.,
1994). MRS sensitivity in detecting UMN involvement in MND/
ALS is reported to be around 86% with a specificity of about 37%,
with the sensitivity somewhat lower at 63% in patients with
PMA and no clear UMN signs clinically (Kaufmann et al., 2004).
For this reason, although the method can be used to monitor dis-
ease progression, the diagnostic value of MRS remains poor
because of considerable overlap in parameters found in MND
patients with those of healthy controls (Rocha and Maia Júnior,
2012).
A potential issue that may affect the interpretation of MRS
results arise from use of metabolite ratios rather than absolute
NAA quantification. The use of ratios such as NAA/Cr or NAA/Cho,
which are relatively easier to achieve with little processing time
required after scanning, rests on the assumption that creatine
and choline concentrations remain constant in the presence of dis-
ease (Chan et al., 2003). A study however, revealed decreases in
values of NAA, creatine and choline in the brainstem of MND/ALS
patients and thus cautioned against the use of concentration ratios
(Hanstock et al., 2002). Furthermore, other studies have demon-
strated that the levels of NAA, choline and creatine all decline with
MND/ALS disease progression resulting in a relatively stable NAA
metabolite ration, thus rendering the use of metabolite ratio for
UMN assessment in longitudinal studies potentially unreliable. In
view of this, absolute NAA quantification may be the preferred
method as technology and software improves that will signifi-
cantly cut back on the scanning and post-processing times that
currently limits its feasibility. In addition, the use of single-voxel
Fig. 10. Proton magnetic resonance spectroscopy (MRS) in ALS compared to control
groups in the left (a) and right (b) precentral gyrus demonstrating a reduction in the
NAA/creatine ratio in patients with ALS. Line within the box represents the median
whilst the 25–75% quartiles are shown by the box. Maximal and minimal values are
represented by the short horizontal lines. Reproduced with permission (Sivak et al.,
2010).
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tivity because of only a relatively small brain being assessed, and
will be improved by the future development of multivoxel MRS
that has greater spatial resolution and allow several different axial
sections to be sampled simultaneously, but may be limited by its
more complex scanning procedure and longer scan time and larger
data sets to process afterwards (Chan et al., 2003; Kaufmann et al.,
2004). This is especially relevant given that reductions in NAA have
also been observed in multiple regions of the CST (Govind et al.,
2012; Stagg et al., 2013) including the brainstem with most
changes seen in the pons and upper medulla in patients with
prominent UMN or bulbar signs (Cwik et al., 1998).4.1.3. Functional MRI
Functional MRI (fMRI) is able to assess physiological function of
the upper motor neurons. It provides high-resolution measures of
neural activity that is reflected by changes in blood flow to local
vasculature in response to activity. During index–thumb opposi-
tion in patients with MND/ALS of lower motor neuron onset,
results were similar to normal controls revealing activation
over M1 and some activation over the sensorimotor cortex. InMND/ALS patients with upper motor neuron signs the activation
appear more widespread, involving the supplementary motor,
premotor, and sensory cortex (Brooks et al., 2000a; Eisen and
Weber, 2001; Agosta et al., 2010a), which was also observed on the
contralateral hemisphere (Schoenfeld et al., 2005). Much of these
changes were thought to be secondary to task-difficulty associated
with the motor impairment and/or a compensatory role of these
recruited extra-motor related brain regions (Agosta et al., 2010a).
In other studies, decreases in regional patterns of activation
were observed in MND/ALS patients during a motor task, with acti-
vation in other regions that positively correlated with UMN bur-
den. Furthermore, activation increased with physical impairment
during follow-up (Tessitore et al., 2006; Lule et al., 2007). Of rele-
vance however, there is difficulty in controlling task performance
in MND patients that may be result in variability of results using
fMRI.
Resting state functional connectivity studies have demon-
strated motor network changes in patients with MND/ALS
(Foerster et al., 2013b). Connectivity appeared to be decreased in
the motor network early in the disease whilst increased connectiv-
ity was observed with loss of interhemispheric inhibition as dis-
ease progressed and disease burden more pronounced
(Mohammadi et al., 2009; Jelsone-Swain et al., 2010; Verstraete
et al., 2010; Agosta et al., 2011; Douaud et al., 2011; Tedeschi
et al., 2012).
With a view to establishing consensus regarding various appli-
cations of novel MRI techniques to the study of MND, and to
explore the possibility of multicentre collaboration, the first Neu-
roimaging Symposium in ALS (NISALS) was held Oxford University,
UK, in November of 2010. There was a recognised need to balance a
multiparametric approach to increase the potential biomarker
yield, with simplicity, reproducibility, and tolerability (Turner
et al., 2011). Consensus was reached about essential and desirable
protocols for MRI as well as the inclusion of critical clinical infor-
mation for MND studies, in order to achieve standardised
approaches to develop robust biomarkers through international
multicentre and longitudinal studies.
4.2. Single-photon emission computed tomography
Using single-photon emission computed tomography (SPECT),
areas of widespread cortical hypoperfusion have been demon-
strated in motor areas as well as frontoparietal regions in patients
with MND/ALS (Anzai et al., 1990; Abe et al., 1993), that were more
pronounced in those with longer disease duration (Ludolph et al.,
1989). The more characteristic reduced uptake confined to the
motor cortex was found only in 29–45% of patients with MND/
ALS (Chan et al., 2003).
4.3. Positron emission tomography
Positron emission tomography (PET) imaging allows qualitative
and quantitative studies of brain metabolism in vivo (Kaufmann
and Mitsumoto, 2002). In MND/ALS patients, frontal hypometabo-
lism has been uniformly demonstrated using 18FDG-PET in all
patients. The most commonly reported regions with hypometabo-
lism involved the perirolandic and frontal brain regions and
appeared to be a sensitive marker of MND/ALS (Dalakas et al.,
1987; Shiozawa et al., 2000; Foerster et al., 2013b; Pagani et al.,
2014; Van Laere et al., 2014) (Fig. 11), with a diagnostic accuracy
of greater than 90% for differentiating MND patients from health
controls (Chio and Traynor, 2015) and sensitivity and specificity
greater than 90% and 80%, respectively (Pagani et al., 2014; Van
Laere et al., 2014). Of relevance, patients clinically diagnosed with
PMA also demonstrated a similar pattern of hypometabolism (Van
Laere et al., 2014) that underscores the presence of subclinical
Fig. 11. 18F-fluorodeoxyglucose PET analysis in ALS patients demonstrating hypometabolism. The images show three-dimensional rendering of the brain cortical surface of
the clusters of voxels in which patients with ALS show hypometabolism compared with healthy controls. Uptake is substantially impaired mainly in the frontal and anterior
cingulate cortex. Reproduced with permission (Chio et al., 2014).
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MND/ALS clinical spectrum. In addition, patients with MND/ALS
also showed clusters of relative hypermetabolism within the cere-
bellum, occipital cortex, upper brain stem, and medial temporal
cortex (Van Laere et al., 2014). Patients with PLS demonstrated a
more widespread abnormality with symmetrically reduced
metabolism bilaterally in the prefrontal cortex, anterior cingulate,
pericentral cortex, and thalamus (Van Laere et al., 2014). One study
proposed that the most discriminating regions (between pheno-
types of MND: ALS, PMA and PLS) were the prefrontal cortex,
thalamus, posterior cingulate, and anterior cingulate (Van Laere
et al., 2014). Reductions in metabolism in frontal lobe regions were
prominent in MND/ALS patients with cognitive impairment espe-
cially those with executive dysfunction such as verbal fluency
(Abrahams et al., 1996; Cistaro et al., 2012), and extensive fron-
totemporal hypometabolism was predictive for a lower survival
(Burrell et al., 2016; Van Weehaeghe et al., 2016). Further studies
however are needed to compare patients with MND to patients
with mimic disorders to better define the sensitivity and specificity
of 18FDG-PET in the diagnosis of MND. Longitudinal studies are also
required to investigate both the neuroradiological course of the
disease using 18FDG-PET but its change in relation to potentially
disease-modifying agents.
15O2 and H215O were originally used to study regional cerebral
blood flow (rCBF), permitting the introduction of activation studies
(Kew et al., 1993). Attention shifted to the utilisation of tracer
ligands such as 18F-6-fluorodopa and 11C-Flumazenil to identify
changes in specific neurochemical and cellular systems in MND/
ALS (Turner and Leigh, 2000). Studies using Flumazenil as a
GABA-A receptor ligand demonstrated similar regions of decreased
tracer uptake in the motor and extramotor regions of the brain
(Cistaro et al., 2014), and profound serotonergic receptor binding
reductions were observed in frontotemporal regions of non-
depressed, non-demented MND/ALS patients (Turner et al., 2005b).5. Combining multiple electrophysiological and imaging
modalities
As the abovementioned novel electrophysiological and imaging
become more readily accessible in clinical practice, it seems likely
that combining structural and functional diagnostic biomarkersmore likely increases the likelihood of objectively demonstrating
UMN dysfunction in MND thereby facilitating earlier diagnosis
and institution of potentially disease-modifying agents (Pohl
et al., 2001b; Kaufmann et al., 2004; Turner et al., 2005a; Furtula
et al., 2013; Grieve et al., 2015; Bae et al., 2016). In a study that
combined structural imaging and electrophysiological approaches
revealed that the presence of precentral gyrus cortical thinning
or paired-pulse TMS abnormalities was evident in 88% of MND
patients, while temporal region cortical thinning or TMS abnormal-
ities were evident in 96% (Grieve et al., 2015). Further, TMS abnor-
malities did not correlate with cortical thinning, suggesting that
functional and structural cortical abnormalities may act as comple-
mentary diagnostic biomarkers of UMN dysfunction in MND/ALS
(Grieve et al., 2015). Prior to this study, another group of investiga-
tors also combined the use of MRS with single-pulsed TMS tech-
niques to examine the presence of UMN abnormalities in
patients with MND/ALS (Pohl et al., 2001b). The authors found that
abnormal MRS findings were present in 53% whilst abnormal TMS
in 63%. Abnormalities in either study was demonstrated in 78%
whilst abnormalities in both in 39%, again suggesting that the
use of a combined imaging and electrophysiological approach
may complement each other and increase the yield of detecting
UMN abnormalities. Of particular relevance, the combined
approach detected UMN abnormalities in 60% of those MND
patients without clinical UMN signs (that included patients in
the suspected and possible EEC categories). Furthermore, more
than 60% of these patients upon follow-up later developed clinical
UMN signs (Pohl et al., 2001b).6. Conclusions and future directions
There remains considerable challenges in the development of a
diagnostic tool that fulfils all of the requirements necessary to con-
stitute a biomarker of UMN dysfunction in MND/ALS patients
(Table 1). It requires replicable data in a large number of patients
with different clinical phenotypes and at various stages of the dis-
ease. Currently, neurophysiological and neuroimaging techniques
utilised in the assessment of UMN function are either not readily
accessible outside a research setting or exhibit poor sensitivity or
specificity in early stage of the disease process. For this reason, for-
mulating a diagnostic algorithm based on the use of these novel
Table 1
Comparison between the techniques used to assess upper motor neuron degeneration in MND.
Technique Sensitivity Specificity Utility in subclinical
UMN phenotypes
Utility in
mimics
Prognostic
value
Limitations/Problems Longitudinal
studies
TMS (threshold-tacking) 73.2–97%1 88.9%1 Yes Yes Yes Limited availability Yes
TST 54%2
Maybe higher in
those with earlier stage3
– Yes No Not studied  Limited in those with significant
LMN loss
 Limited number of patients and studies
to date
No
PSTH – Low No Yes Not studied Lack specificity and abnormalities seen in
other CNS disorders
Yes
T2 MRI 640%4 670%4 No No Not studied Low sensitivity No
VBM/SBM MRI 25%5 - No No Not studied  Conflicting data
 Late stage disease mainly
 Small patient numbers
No
DTI MRI 25–86%2,6,7 P70%6,7 Yes No Yes  Non-standardised data
 Limited patient numbers
 Late stage disease mainly
Yes
MTI–MRI 80%8 100%8 No No No  Very small numbers to date
 Needs further studies
No
MRS 71–86%9,10 37–75%9,10 Yes Yes No  Considerable overlap between healthy
controls and patients
 Limited patient numbers
 Late stage disease mainly
Yes
fMRI - - No No No Diagnostic value uncertain No
SPECT 29–45%4 - No No No Diagnostic value uncertain No
PET 89–95%11,12 P80%11,12 Yes No No Need to compare with MND mimics No
TMS, transcranial magnetic stimulation; TST, triple stimulation technique; PSTH, peristimulus time histograms; MRI, magnetic resonance imaging; VBM, volume-based
morphometry; SBM, surfaced-based morphometry; DTI, diffusion-tensor imaging; MTI, magnetisation transfer imaging; MRS, magnetic resonance spectroscopy; MTI,
magnetic transfer imaging; fMRI, functional MRI; SPECT, single-photon emission computed tomography; PET, positron emission tomography.
Table References:
1 Menon et al. (2015a).
2 Furtula et al. (2013).
3 Komissarow et al. (2004).
4 Chan et al. (2003).
5 Chen and Ma (2010).
6 Foerster et al. (2013a).
7 Foerster et al. (2014).
8 da Rocha et al. (2004).
9 Cervo et al. (2015).
10 Pohl et al. (2001b).
11 Pagani et al. (2014).
12 Van Laere et al. (2014).
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gely on the regional availability and accessibility of these
techniques.
Of relevance, most neuroimaging studies to date have involved
relatively small numbers of patients with long disease duration
that may result in skewed sampling, and may explain some of
the discrepant neuroimaging results in the literature, and poten-
tially limiting the generalizability of the findings (Foerster et al.,
2013b). International efforts have produced a consensus statement
paper from the Neuroimaging Society in ALS to facilitate neu-
roimaging biomarker development that will be standardised across
centres (Filippi et al., 2015). More recently, a multicentre DTI study
showed that by applying correction procedures to regress and
account for centre-specific variability, it is possible to increase
the sensitivity and specificity of DTI findings, thereby suggesting
the feasibility to pool scans across sites, despite significant differ-
ences across protocols, to facilitate multisite collaboration
(Hornberger and Kiernan, 2016; Muller et al., 2016).
In addition, UMN abnormalities demonstrated in many neu-
roimaging studies have mainly been observed in those with clini-
cally apparent UMN features (majority of patients in the
clinically probably or definite categories) with the changes corre-
lating to the degree of UMN scores, casting doubt on their utility
in uncovering reliable changes in patient’s in the early stages
where LMN features predominate. The recruitment pool also dif-
fered in those patients selected for neuroimaging studies that werepredominantly from retrospective cohorts of clinical patients
referred to imaging centres, thereby explaining why majority were
in the later stages of disease. This is in comparison to many electro-
physiological studies that were prospective assessment of a large
number of patients that were referred to specialised MND/ALS aca-
demic and research centres with a substantial proportion in their
early stages. Furthermore, the ability to distinguish MND from
mimics in neuroimaging studies have not been sufficiently
explored (Chio and Traynor, 2015). Further limitations of current
neuroimaging studies are attributable to respiratory involvement
in MND patients that result in their inability to take part in longi-
tudinal studies as their disease progresses to a later stage when
lying flat for the study poses significant issues. Moreover, there
are issue relating to the availability and cost of installing these
advanced imaging modalities outside of research or academic
facilities.
Without doubt, it is likely that in searching for an ideal diagnos-
tic biomarker of UMN degeneration in MND, there will be a need
for collaboration amongst neurologists, neuroimaging specialists
and neurophysiologists, and that a combination of electrophysio-
logical and neuroimaging modalities will prove to be the most
attractive approach as they become more widespread and accessi-
ble to the clinical setting in the not too distant future. A multi-
modality structural and functional approach may also prove
useful to further our understanding of the pathophysiological
mechanisms and natural history of MND in a way that may
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disease-causing pTDP-43 protein aggregates in the corticomo-
toneurons and their subsequent dissemination via axonal transport
to more distant sites such as the spinal cord or other brain regions
(Braak et al., 2013). Such multimodal approaches may also facili-
tate comprehensive longitudinal studies thereby paving the way
for the development of therapeutic biomarkers to investigate ner-
vous system changes in response to potential novel therapeutics.
Until then, neurologists will need to utilise whichever modality
that is currently accessible, and being able to appropriately apply
the research results when addressing individual patients but keep-
ing in mind their current limitations in clinical practice. Based on
the authors experience and the current review, a combination of
threshold tracking TMS and FDG-PET imaging represent an attrac-
tive approach given their high sensitivity and specificity based on
large numbers of patients studied, their relative availability (par-
ticularly with PET imaging) and cost, as well as the ability for the
tests to complement each other. In particular, PET studies are able
to identify a larger area of abnormality (motor and extramotor)
that is not captured by a single TMS parameter from a specific cor-
tical region examined, thereby allowing for a more comprehensive
approach to studying disease pathophysiology, natural history and
the effects of disease-modifying agents. After decades of seemingly
incremental progress, it now seems tangible that objective
biomarkers of UMN dysfunction will be available at the clinic, that
in turn will facilitate an earlier diagnosis of MND/ALS, more timely
commencement of neuroprotective therapy and in turn, enrolment
into future trials and novel treatment strategies.
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